Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to ...

Tax Deducted at Source (TDS) is a scheme launched by the Government of India for deduction of tax at the very source of income. It ensures each payment made will carry some portion of taxes being ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Looking to shave $65 million from its annual expenditures while streamlining the first stage of its two-level grant review process, the U.S. NIH is proposing to centralize the peer review of all ...

Artificial intelligence (AI) and the Internet of Things (IoT) are about to revolutionize the biopharmaceutical industry.

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...